CAS 1425381-60-7
:gusacitinib
Description:
Gusacitinib is a small molecule inhibitor primarily targeting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2, which play crucial roles in the signaling pathways of various cytokines and growth factors. This compound is being investigated for its potential therapeutic applications in autoimmune diseases and certain inflammatory conditions. Its mechanism of action involves the modulation of immune responses by inhibiting the JAK-STAT signaling pathway, thereby reducing inflammation and altering immune cell function. Gusacitinib is characterized by its selective inhibition, which aims to minimize side effects associated with broader immunosuppressive therapies. The substance is typically administered orally and has undergone various phases of clinical trials to evaluate its efficacy and safety profile. As with many investigational drugs, the pharmacokinetics, metabolism, and potential drug interactions are critical areas of study to ensure optimal therapeutic outcomes. Overall, gusacitinib represents a promising avenue in the development of targeted therapies for complex immune-mediated disorders.
- GUSACITINIB
- 1-[5,6-Dihydro-4-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5-oxopyrimido[4,5-d]pyridazin-2-yl]-4-piperidineacetonitrile
- 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile
- 4-Piperidineacetonitrile, 1-[5,6-dihydro-4-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5-oxopyrimido[4,5-d]pyridazin-2-yl]-
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formula:C24H28N8O2Purity:98.06% - 99.94%Color and Shape:SolidMolecular weight:460.53Gusacitinib
CAS:<p>Gusacitinib is a drug that belongs to the class of inhibitor drugs that blocks the activity of Janus kinase (JAK) and has been shown to be effective against alopecia areata, a disease characterized by hair loss. Gusacitinib also inhibits other intracellular targets such as chemoattractant protein and inflammatory lesion. Gusacitinib was developed from a family of compounds that were originally designed for the treatment of cancer. It showed long-term efficacy in inhibiting the growth of cancer cells in mice and clinical studies have shown promising results for its use in treating inflammatory skin diseases.</p>Formula:C24H28N8O2Purity:Min. 95%Molecular weight:460.53 g/mol



